Gilead Sciences, today announced that its Phase II integrase inhibitor drug, which is for once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective. The current study of 71 HIV-infected, antiretroviral treatment-naïve adults was compared to the Quad with Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). this data was collected in 24-week and efficacy of the Quad met the statistical criteria of non-inferiority as compared to Atripla based on the proportion of subjects with HIV RNA levels (viral load) of less than 50 copies/mL......though this is good news but from last year I have observed that Gilead has very few compounds in pipeline compared to GSK which has become very active in this Anti-viral space in a span of 10-11 months.
For more information on Gilead Sciences data report read in
http://www.clinicaspace.com/news_story.aspx?NewsEntityId=166874
No comments:
Post a Comment